Skip to content
Open access

Seed amplification of released alpha-synuclein strains reveals genotype-specific differences in Parkinson’s disease neurons

Sep 2026 · Frontiers in Aging Neuroscience · Vol 18 · 0 citations · 65 references
Medicine

TL;DR

Findings indicate that genotype-specific cellular responses differentially shape the structural properties of released α-syn in a manner that determines amplification responses, enabling inter-group discrimination at the single-molecule level.

Abstract

Parkinson’s disease is one of a group of diseases collectively termed α-synucleinopathies, all of which are characterized by abnormal accumulation of toxic α-synuclein (α-syn) assemblies which are thought to follow a prion-like propagation model and drive neuronal death. Both intrinsic strain properties and the genetic background of affected individuals are hypothesized to influence α-syn aggregate accumulation, propagation, and extracellular release. As such, the aim of this study is to characterize how different genetic backgrounds modulate α-syn aggregate accumulation and release in response to treatment with different α-syn strains. iPSC-derived neurons from five different groups were employed (healthy non-PD controls (NPC), idiopathic PD (iPD), GBA1 N370S, LRRK2 G2019S and SNCA A53T) (n = 15 cell lines, three lines per group). Individual aggregates in conditioned medium (CM) were measured using a single-particle detection system to quantify released α-syn species and assess strain persistence across genotype groups. Seed amplification assay (SAA) was then applied and linear discriminant analysis (LDA) of single particle properties from CM of α-syn fibril-treated neurons was used to discriminate between groups. α-Syn released into CM showed strain persistence in LRRK2 G2019S and GBA1 N370S genotype groups, while SNCA A53T neurons exhibited evidence of strain remodeling. Interestingly, amplification-response Δ-feature analysis of single particle properties showed group discrimination beyond either pre- or post- amplification measurements independently, reaching a maximum LOO-CV accuracy of 66.7% (3.3 × chance level) at day 10 post-treatment in CM from fibrils-treated neurons. These findings indicate that genotype-specific cellular responses differentially shape the structural properties of released α-syn in a manner that determines amplification responses, enabling inter-group discrimination at the single-molecule level.

Read PDF

Similar papers

Open access Sep 2026

Cellular prion protein levels modulate nigrostriatal vulnerability to α-synuclein oligomers in Parkinson’s disease

PrPC expression levels are identified as an important modulator of nigrostriatal vulnerability and neuroinflammatory phenotype in response to αSynO, supporting the hypothesis that PrPC contributes to αSynO-mediated pathogenic mechanisms.

Flavio de Souza Júnyor, F. Leser, Sarah de Souza Albuquerque et al. · 0 citations
Open access Aug 2026

Targeted degradation of alpha-synuclein impedes PFF-induced aggregation

The Affinity-directed PROtein Missile system is employed and targeted degradation of α-synuclein impedes the pre-formed fibril (PFF)-induced aggregation of α-synuclein in primary neurons derived from rats expressing human α-synuclein.

Bill Carton, Géraldine Gelders, Gajanan Sathe et al. · 0 citations
Open access Sep 2026

Label-Free Proteomics of α-Synuclein-Expressing Caenorhabditis elegans Model Uncovers Conserved Pathophysiological Pathways in Parkinson’s Disease

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease in the elderly population, characterized by a wide variety of motor and non-motor symptoms. Its complex biochemical and molecular mechanisms make it challenging to study PD directly in patients or to replicate it in vitro, underscoring the...

Iverson Conrado Bezerra, Maria Luiza de Lima Vitorino, Josivan Barbosa de Farias et al. · 0 citations
Open access Sep 2026

Urine-Derived Neuronal Extracellular Vesicle α-Synuclein Seed Amplification Assay for Synucleinopathies: A Non-Invasive Biomarker Study.

BACKGROUND α-Synuclein aggregation is a pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). Although pathogenic α-synuclein seeds can be detected by real-time quaking-induced conversion (RT-QuIC), current assays primarily rely on cerebrospinal fluid, whose i...

H. Tran, Huu Dat Nguyen, T. Nguyen et al. · 0 citations
Open access Aug 2026

Multiple system atrophy-derived α-synuclein fibrils are more potent and display oligodendrocyte cell tropism compared to Parkinson's disease-derived fibrils.

Interestingly, amplified material from MSA brains induced significantly more oligodendroglial pSyn aggregates than amplified material from PD brains, and mice injected with the fibril polymorph, showed mild changes in microglial reactivity.

Anne-Line Strange Laursen, K. Willén, Alexis Fenyi et al. · 0 citations
Open access Sep 2026

Spreading alpha-synuclein oligomers trigger astrocyte/microglial changes and astrocyte-glutamatergic neuron system dysfunction in an age-related manner

A model in which α-syn oligomer spreading, amplified by aging, simultaneously disrupts the astrocyte–glutamatergic neuron axis and drives microglia into a senescent DAM-like state is proposed, and candidate gene sets for both processes are provided for further investigation of glial dysfunction in PD.

Jaehyun LeeBae, Verena Bopp, Alicia Goreth et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.